OmniAb, Inc. (OABIW) stock
OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value
$0.41−0.01 (-2.38%)
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
OmniAb's revenue for the twelve months ending Sep 30, 2026 was $40.21M, up 90.6% year over year. For fiscal 2025 it was $18.67M, down 29.3% from the year before. The highest annual figure on record is $59.08M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67M | -29.3% |
| FY2024 | Dec 31, 2024 | $26.39M | -22.8% |
| FY2023 | Dec 31, 2023 | $34.16M | -42.2% |
| FY2022 | Dec 31, 2022 | $59.08M | +70.0% |
| FY2021 | Dec 31, 2021 | $34.75M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $3.99M | +78.3% |
| Q2 FY2026 | Jun 30, 2026 | $13.42M | +244.2% |
| Q1 FY2026 | Mar 31, 2026 | $14.43M | +247.3% |
| Q4 FY2025 | Dec 31, 2025 | $8.38M | -22.5% |
| Q3 FY2025 | Sep 30, 2025 | $2.24M | -46.3% |
| Q2 FY2025 | Jun 30, 2025 | $3.90M | -48.8% |
| Q1 FY2025 | Mar 31, 2025 | $4.15M | +9.3% |
| Q4 FY2024 | Dec 31, 2024 | $10.80M | +124.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.17M | -23.8% |
| Q2 FY2024 | Jun 30, 2024 | $7.61M | +9.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.80M | -77.5% |
| Q4 FY2023 | Dec 31, 2023 | $4.82M | -86.4% |
| Q3 FY2023 | Sep 30, 2023 | $5.48M | -20.7% |
| Q2 FY2023 | Jun 30, 2023 | $6.95M | -3.5% |
| Q1 FY2023 | Mar 31, 2023 | $16.92M | +75.8% |
| Q4 FY2022 | Dec 31, 2022 | $35.35M | – |
| Q3 FY2022 | Sep 30, 2022 | $6.91M | – |
| Q2 FY2022 | Jun 30, 2022 | $7.20M | – |
| Q1 FY2022 | Mar 31, 2022 | $9.62M | – |